Navigation Links
Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
Date:5/6/2013

INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter , Ph.D., chairman, president, and chief executive officer, will undergo scheduled surgery for a dilated aorta on Monday, May 13, 2013. This condition was found during unrelated testing and has been asymptomatic. Lechleiter is expected to make a full recovery and return to his duties later this summer.

In accordance with the company's bylaws, Derica W. Rice , executive vice president, Global Services and chief financial officer, will assume the additional role of acting chief executive officer during Lechleiter's surgery and recuperation period.  Ellen R. Marram, currently the board's lead independent director, will serve as acting chairperson of the board of directors. She was appointed as lead independent director in April 2012.

Rice, 48, has more than 22 years of service with Eli Lilly and Company, including leadership roles in finance and general management. He became chief financial officer in 2006 and assumed leadership of the company's global services organization in 2010.

Marram, 66, is president of the Barnegat Group LLC, her business advisory firm, and she is also the former CEO of two consumer products companies. She has served on the Lilly board since 2002 and is also a member of the board of directors of Ford Motor Company and The New York Times Company.

"I am grateful to be under the care of a world-class medical team located right here in Indianapolis," said Lechleiter. "The board of directors and I have the utmost confidence in Ellen, Derica, and our Lilly leadership team.  The company will be in very good hands during my leave. I look forward to returning to work following my recovery."

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

Refer to: (317) 433-9899, egs@lilly.comEdward Sagebiel

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... Healthcare is in flux. The GOP wants ... mass media launching of story movements to highlight what's most unfair about healthcare. ... such a movement can generate the network power to improve healthcare policies in ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that serve communities in and around the greater Phoenix metropolitan region, is announcing ... Connection. , The mission of the Homeless Youth Connection is to promote community ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... wrinkles and deep lines by smoothing and tightening the skin of the face ... there to address facial aging with very little downtime, Silhouette Instalift is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
Breaking Medicine News(10 mins):